Hutchison China MediTech Ltd – (HCM) Given Consensus Rating of “Strong Buy” by Brokerages

Hutchison China MediTech Ltd – (NASDAQ:HCM) has been given a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.

Analysts have set a one year consensus target price of $41.00 for the company, according to Zacks. Zacks has also assigned Hutchison China MediTech an industry rank of 166 out of 265 based on the ratings given to related companies.

How to Become a New Pot Stock Millionaire

A number of research firms have weighed in on HCM. BidaskClub downgraded shares of Hutchison China MediTech from a “buy” rating to a “hold” rating in a research report on Tuesday, March 20th. Zacks Investment Research downgraded shares of Hutchison China MediTech from a “hold” rating to a “sell” rating in a research report on Thursday, March 15th.

Hutchison China MediTech stock opened at $29.67 on Friday. The company has a market capitalization of $3,976.59, a PE ratio of -134.86 and a beta of 0.40. Hutchison China MediTech has a 1 year low of $18.00 and a 1 year high of $42.25.

A number of large investors have recently added to or reduced their stakes in the business. Castleark Management LLC acquired a new stake in Hutchison China MediTech during the 4th quarter valued at approximately $177,000. Geode Capital Management LLC acquired a new stake in Hutchison China MediTech during the 4th quarter valued at approximately $258,000. Folger Hill Asset Management LP increased its position in Hutchison China MediTech by 12.6% during the 4th quarter. Folger Hill Asset Management LP now owns 60,342 shares of the company’s stock valued at $2,379,000 after purchasing an additional 6,772 shares during the period. Perceptive Advisors LLC acquired a new stake in Hutchison China MediTech during the 3rd quarter valued at approximately $273,000. Finally, Mckinley Capital Management LLC Delaware acquired a new stake in Hutchison China MediTech during the 4th quarter valued at approximately $1,237,000. 7.46% of the stock is owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This article was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this article on another site, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.tickerreport.com/banking-finance/3338089/hutchison-china-meditech-ltd-hcm-given-consensus-rating-of-strong-buy-by-brokerages.html.

Hutchison China MediTech Company Profile

Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments.

Get a free copy of the Zacks research report on Hutchison China MediTech (HCM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Hutchison China MediTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hutchison China MediTech and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

The Providence Service  Upgraded at BidaskClub
The Providence Service Upgraded at BidaskClub
Kinder Morgan’s  Buy Rating Reiterated at Bank of America
Kinder Morgan’s Buy Rating Reiterated at Bank of America
Spectrum Brands  Price Target Cut to $112.00
Spectrum Brands Price Target Cut to $112.00
Texas Capital Bancshares  Given New $100.00 Price Target at SunTrust Banks
Texas Capital Bancshares Given New $100.00 Price Target at SunTrust Banks
Alcoa  Price Target Increased to $0.00 by Analysts at JPMorgan Chase
Alcoa Price Target Increased to $0.00 by Analysts at JPMorgan Chase
Autodesk  Price Target Increased to $150.00 by Analysts at Oppenheimer
Autodesk Price Target Increased to $150.00 by Analysts at Oppenheimer


Leave a Reply

© 2006-2018 Ticker Report. Google+.